Australia markets closed

Edwards Lifesciences Corporation (E1WL34.SA)

São Paulo - São Paulo Delayed price. Currency in BRL
Add to watchlist
116.90-0.88 (-0.75%)
At close: 04:12PM BRT
Full screen
Previous close117.78
Open116.90
Bid116.96 x N/A
Ask117.45 x N/A
Day's range116.90 - 116.90
52-week range76.40 - 120.12
Volume2
Avg. volume13
Market cap282.183B
Beta (5Y monthly)1.11
PE ratio (TTM)9.39
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR

    NEW YORK, June 05, 2024--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient’s annulus size or sex. These data were presented during the late-breaking clinical

  • PR Newswire

    BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Edwards Lifesciences (NYSE: EW), today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.

  • Business Wire

    Edwards Lifesciences to Sell Critical Care to BD

    IRVINE, CA, June 03, 2024--Edwards Lifesciences (NYSE: EW) today announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.